ABCA1 p.Arg282*
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 21875686
[PubMed]
Tietjen I et al: "Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT."
No.
Sentence
Comment
117
COOHA B T929I H2N R587W B A M1091T C1477R K776N N935S S1181F IVS24+1 G>C V2244I R282X D571G M640L S930F M968T R1615WIVS16-5 CA>del ABCA1 Transmembrane domain ATP-binding domain Q597R A) AA 1 AA 267 K130del L202P 74 90 98 112 122 145 167 189 211 215 233 253 APOA1 Negative charge domain Alpha-helix E222K E134DT37M 140 178 206 41127 104 121 165 200 229 360 391 Y135N V246F 127 206 369 401 Catalytic triad R322C L338H V371MV52M Y107X A117T T147I V333M Phe Leu Asp His AA 1 AA 440 R159Q I202T LCAT Alpha helixBeta sheet B) 419I.Tietjenetal./BiochimicaetBiophysicaActa1821(2012)416-424 3.4.
X
ABCA1 p.Arg282* 21875686:117:80
status: NEW
PMID: 20880529
[PubMed]
Candini C et al: "Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol."
No.
Sentence
Comment
76
Patients (gender, age) Amino acida (nucleotidea ) change TC TG LDL-c HDL-c Clinical manifestations of TD CVD Other relevant clinical data Homozygotes Patient 1 (female, 42) p.L1056P (c.3167T > C) 2.4 0.9 1.99 <0.10 Absent CAD Thrombocytopenia Patient 2 (male, 40) p.Wl747X (c.5240G > A) 1.76 1.93 0.52 0.1-0.3 Neuropathy, splenomegaly, thrombocytopenia Mild stenosis (20-30%) of coronary arteries None Patient 3 (male, 55) p.F593L (c.1779C > G) 4.4 1.4 3.6 <0.10 Absent CAD None p.E1253K (c.3757G > A) Compound heterozygotes Patient 4 (female, 63) p.Q1038X (c.3112C > T) 6.68 2.72 5.4 <0.10 Absent None None p.N1800H (c.5398A > C) [32] Patient 5 (female, 28) p.T1512M (c.4535C > T) 4.42 1.83 3.46 0.1 Absent None None p.N1800H (c.5398A > C) [32] p.C978fsX988 (c.2934delT) Patient 6 (female, 17) p.D575G (c.1724A > G) 4.96 2.84 4.35 <0.10 Absent None DM1 p.C1941R(c.5821T > C) Heterozygotes Patient 7 (male, 42) p.S100C (c.299C > G) 8.5 8.7 4.3 0.3 N.A. None None Patient 8 (male, 58) p.E1172D (c.3516G > C) [33] 6.4 2.7 4.1 0.9 N.A. None None Patient 9 (male, 35) p.S1181F (c.3542C > T) [17] 2.9 0.31 1.88 0.88 N.A. None None Patient 10 (male, 48) p.C1477R (c.4429T > C) [13] 2.01 1.4 0.92 0.46 N.A. CAD None Patient 11 (male, 68) p.V1858A (c.5573T > C) 4.9 3.78 2.41 0.75 N.A. CAD None Patient 12 (female, 36) p.N1800H (c.5398A > C) [32] 4.6 1.2 4 <0.10 N.A. None DM2, obesity Patient 13 (male, 67) p.R282X (c.844C > T) [34] 3.2 1.21 2.14 0.51 N.A. None DM2 Patient 14 (female, 42) p.W424X (c.1272G > A) 2.07 1.04 1.39 0.21 N.A. None None Patient 15 (female, 52) N.A. - (IVS11 - 1G > A) 5.51 3.51 3.28 0.56 N.A. None Hypothyroidism, hypertension Patient 16 (female, 54) N.A. - (IVS48 + 2T > C) 3.29 1.92 1.94 0.49 N.A. None DM2, hypertension a Nomenclature based on guidelines of Human Genome Variation Society.
X
ABCA1 p.Arg282* 20880529:76:1402
status: NEW89 In ABCA1, we identified 14 novel and 5 known genetic variations in 16 subjects including one frameshift (p.C978fsX988), 2 splice-site (IVS11-1G > C and IVS48 + 2T > C), 4 nonsense (p.R282X, p.W424X, p.Q1038X, p.Wl747X) and 12 missense variations (p.S100C, p.D575G, p.F593L, p.L1056P, p.E1172D, p.S1181F, p.E1253K, p.C1477R, p.T1512M, p.N1800H, p.V1858A, p.C1941R).
X
ABCA1 p.Arg282* 20880529:89:183
status: NEW
PMID: 19765707
[PubMed]
Cameron J et al: "Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532C."
No.
Sentence
Comment
0
Atherosclerosis 209 (2010) -166 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532C Jamie Camerona , Trine Ranheima , Bente Halvorsenb,c , Mari Ann Kulsetha , Trond P. Lerena , Knut Erik Bergea,* a Medical Genetics Laboratory, Department of Medical Genetics, Rikshospitalet, Oslo University Hospital, NO-0027 Oslo, Norway b Research Institute of Internal Medicine, Rikshospitalet, Oslo University Hospital, Norway c University of Oslo, Norway a r t i c l e i n f o Article history: Received 10 July 2009 Received in revised form 18 August 2009 Accepted 19 August 2009 Available online 29 August 2009 Keywords: ABCA1 gene Cholesterol efflux HDL cholesterol Mutation Tangier disease a b s t r a c t Background: Inherited low levels of high density lipoprotein (HDL) cholesterol may be due to mutations in the genes encoding the ATP-binding cassette transporter A1 (ABCA1), apolipoprotein (apo) A-I or lecithin:cholesterol acyltransferase (LCAT).
X
ABCA1 p.Arg282* 19765707:0:218
status: NEW5 Results: The proband was a compound heterozygote for ABCA1 mutations R282X (c.844 C>T) and Y1532C (c.4595 A>G).
X
ABCA1 p.Arg282* 19765707:5:69
status: NEW9 Conclusion: Compound heterozygosity for the nonsense mutation R282X and the missense mutation Y1532C in the ABCA1 gene causes Tangier disease.
X
ABCA1 p.Arg282* 19765707:9:62
status: NEW10 R282X has a detrimental effect on the function of ABCA1 since a premature stop codon is introduced.
X
ABCA1 p.Arg282* 19765707:10:0
status: NEW66 However, DNA sequencing of the ABCA1 gene suggested that the proband was a compound heterozygote for the nonsense mutation R282X (c.844 C>T) in exon 9 and the missense mutation Y1532C (c.4595 A>G) in exon 34.
X
ABCA1 p.Arg282* 19765707:66:123
status: NEW67 R282X has previously been reported by Altilia et al. [19] as a cause of defective function of ABCA1, while Y1532C is a novel mutation.
X
ABCA1 p.Arg282* 19765707:67:0
status: NEWX
ABCA1 p.Arg282* 19765707:67:100
status: NEW69 With respect to the genotypes, the proband`s mother and brother were both heterozygous for mutation R282X, while his father and daughter were heterozygous for mutation Y1532C.
X
ABCA1 p.Arg282* 19765707:69:100
status: NEW84 Together with the finding that none of 100 healthy unrelated individuals with levels of total serum cholesterol ≤6.5 mmol/l, HDL cholesterol between 1.2 and 1.8 mmol/l and triglycerides ≤3.0 mmol/l were found to be heterozygous for R282X or Y1532C in the ABCA1 gene, our findings suggest that the proband had Tangier disease.
X
ABCA1 p.Arg282* 19765707:84:246
status: NEW89 Mutation R282X has recently been described in a Tangier disease patient, who was also heterozygous for mutation IVS2+5G>C [19].
X
ABCA1 p.Arg282* 19765707:89:9
status: NEWX
ABCA1 p.Arg282* 19765707:89:94
status: NEW90 R282X introduces a premature stop codon in the predicted large 1st extracellular loop of ABCA1.
X
ABCA1 p.Arg282* 19765707:90:0
status: NEW91 mRNA analyses of fibroblasts failed to detect a transcript from the allele harboring mutation R282X, which the authors attributed to nonsense-mediated mRNA Fig. 3.
X
ABCA1 p.Arg282* 19765707:91:94
status: NEW98 Thus, R282X should be considered to be a pathogenic mutation.
X
ABCA1 p.Arg282* 19765707:98:6
status: NEWX
ABCA1 p.Arg282* 19765707:98:138
status: NEW100 It cannot be excluded that this mutation could be a normal genetic variant and that Tangier disease in the proband was caused by mutation R282X and an unidentified mutation in the ABCA1 gene.
X
ABCA1 p.Arg282* 19765707:100:138
status: NEW124 Albrecht et al. [23] showed that mutation L1379F, which is also predicted to be in the 4th extracellular loop, was present at reduced levels at the cell surface.
X
ABCA1 p.Arg282* 19765707:124:169
status: NEW126 In conclusion, we have identified the first patient with Tangier disease of Norwegian origin, due to compound heterozygosity for the previously described ABCA1 mutation R282X [19], and the novel ABCA1 mutation Y1532C.
X
ABCA1 p.Arg282* 19765707:126:169
status: NEW64 However, DNA sequencing of the ABCA1 gene suggested that the proband was a compound heterozygote for the nonsense mutation R282X (c.844 C>T) in exon 9 and the missense mutation Y1532C (c.4595 A>G) in exon 34.
X
ABCA1 p.Arg282* 19765707:64:123
status: NEW65 R282X has previously been reported by Altilia et al. [19] as a cause of defective function of ABCA1, while Y1532C is a novel mutation.
X
ABCA1 p.Arg282* 19765707:65:0
status: NEW82 Together with the finding that none of 100 healthy unrelated individuals with levels of total serum cholesterol ࣘ6.5 mmol/l, HDL cholesterol between 1.2 and 1.8 mmol/l and triglycerides ࣘ3.0 mmol/l were found to be heterozygous for R282X or Y1532C in the ABCA1 gene, our findings suggest that the proband had Tangier disease.
X
ABCA1 p.Arg282* 19765707:82:244
status: NEW87 Mutation R282X has recently been described in a Tangier disease patient, who was also heterozygous for mutation IVS2+5G>C [19].
X
ABCA1 p.Arg282* 19765707:87:9
status: NEW88 R282X introduces a premature stop codon in the predicted large 1st extracellular loop of ABCA1.
X
ABCA1 p.Arg282* 19765707:88:0
status: NEW96 Thus, R282X should be considered to be a pathogenic mutation.
X
ABCA1 p.Arg282* 19765707:96:6
status: NEW
PMID: 16704350
[PubMed]
Brunham LR et al: "Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis."
No.
Sentence
Comment
554
Conversely, a small number of mutations are associated with less than 50% of control HDL cholesterol, specifically M1091T, G1216V, and the truncation mutations R2144X, R282X, and R909X.
X
ABCA1 p.Arg282* 16704350:554:168
status: NEW555 Since a complete loss of function allele would be expected to result in a 50% reduction in HDL levels, a greater than 50% reduction in HDL is most likely explained by a dominant negative allele, in which TABLE 3 Patient phenotypes associated with heterozygous ABCA1 mutations Mutation HDL (mmol/L) HDL (% of control) Number of patients M1091T 0.48 ± 0.5 30 ± 30 4 G1216V 0.50 40 1 R2144X 0.56 ± 0.2 41 ± 18 12 R282X 0.52 41 1 R909X 0.59 ± 0.3 42 ± 19 5 K776N 0.55 ± 0.1 47 ± 5 2 R587W 0.61 ± 0.1 47 ± 8 7 S364C 0.60 48 1 P1065S 0.80 51 1 c-ter deletion 0.75 53 1 N1800H - 56.5 33 P85L 0.72 ± 0.4 57 ± 33 5 Del693L 0.79 ± 0.2 57 ± 15 8 D1289N 0.80 ± 0.1 59 ± 12 4 R2081W 0.80 ± 0.1 59 ± 12 4 2203X 0.80 ± 0.2 59 ± 20 4 DelED1893,4 0.77 ± 0.2 59 ± 18 8 2145X 0.82 ± 0.1 59 ± 9 4 A1046D 0.70 ± 0.1 60 ± 8 2 Q597R 0.82 ± 0.1 60 ± 5 5 C1477R 0.82 ± 0.2 61 ± 15 9 IVS25 + 1G > C 0.78 ± 0.1 62 ± 12 4 D1099Y 0.83 ± 0.3 63 ± 21 5 1552X 1.00 64 1 F2009S 0.82 ± 0.2 64 ± 19 6 R587W 0.86 ± 0.1 65 ± 17 2 R1068H 0.90 ± 0.3 67 ± 26 9 N935S 1.00 ± 0.3 74 ± 16 7 T929I 1.01 ± 0.2 76 ± 7 8 1284X 1.11 ± 0.2 83 ± 14 5 A937V 1.15 ± 0.6 85 ± 28 2 R1680W 1.22 ± 0.2 87 ± 17 3 635X 1.24 ± 0.5 90 ± 32 7 W590S 1.32 ± 0.6 103 ± 46 15 the mutant protein actually interferes with the activity of the remaining wild-type protein.
X
ABCA1 p.Arg282* 16704350:555:433
status: NEW
No.
Sentence
Comment
65
TD 1210-1217 8bp del 9 277X truncation [65] TD 1239 C/T 9 R282X truncation [73.]
X
ABCA1 p.Arg282* 12840658:65:58
status: NEW
PMID: 12576507
[PubMed]
Altilia S et al: "Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene."
No.
Sentence
Comment
1
254 Journal of Lipid Research Volume 44, 2003 This article is available online at http://www.jlr.org Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 ϩ5GϾC mutation in ABCA1 gene Serena Altilia,* Livia Pisciotta,† Rita Garuti,* Patrizia Tarugi,* Alfredo Cantafora,§ Laura Calabresi,** Jacopo Tagliabue,†† Sergio Maccari,§§ Franco Bernini,*** Ilaria Zanotti,*** Carlo Vergani,†† Stefano Bertolini,† and Sebastiano Calandra1,** Department of Biomedical Sciences,* University of Modena and Reggio Emilia; Department of Internal Medicine,† University of Genoa; National Institute of Health,§ Rome; Department of Pharmacological Sciences,** Center "E. Grossi Paoletti," University of Milan; Ospedale Maggiore-IRCCS,†† Milan; Sant`Anna Hospital,§§ Castelnuovo Monti, Reggio Emilia; and Departments of Pharmacological*** and Biological Sciences and Applied Chemistries, University of Parma, Italy Abstract Two point mutations of ABCA1 gene were found in a patient with Tangier disease (TD): i) GϾC in intron 2 (IVS2 ؉5GϾC) and ii) c.844 CϾT in exon 9 (R282X).
X
ABCA1 p.Arg282* 12576507:1:1194
status: NEW79 The R282X mutation and the cosegregating haplotype are indicated by red color (see sequence analysis in Fig. 3).
X
ABCA1 p.Arg282* 12576507:79:4
status: NEW165 The sequence of ABCA1 gene revealed that proband I.1 (Family 1) was a compound heterozygote for: i) a GϾC transversion at the 5th nucleotide of intron 2 (IVS2 ϩ5GϾC), and ii) a c.844 CϾT transition in exon 9, which converts the arginine codon at position 282 into a termination codon (R282X) (Fig. 3).
X
ABCA1 p.Arg282* 12576507:165:309
status: NEW168 The c.844 CϾT mutation (R282X) introduces a new AflIII restriction site.
X
ABCA1 p.Arg282* 12576507:168:30
status: NEW170 The proband`s brother was heterozygous for the nonsense mutation in exon 9 (R282X).
X
ABCA1 p.Arg282* 12576507:170:76
status: NEW174 Haplotype analysis The genotyping of five polymorphic markers close to or within the ABCA1 gene demonstrated: i) the IVS2 ϩ5GϾC mutation co-segregates with haplotype a; ii) the probands of Family 1 and Family 2 share this haplotype; iii) the nonsense mutation (R282X) cosegregates with haplotype b (Fig. 1).
X
ABCA1 p.Arg282* 12576507:174:273
status: NEW179 Skin fibroblasts from a control subject, proband I.1 of Family 1 (IVS2 ϩ5GϾC/ R282X), and another TD patient (homozygous for R587W) reported previously (13) were labeled with [3H]cholesterol and then incubated in the presence or in the absence of 22-hydroxycholesterol and 9-cis- retinoic acid (22ch/RA).
X
ABCA1 p.Arg282* 12576507:179:90
status: NEW185 Analysis of cDNA Unexpectedly, the sequence of the cDNA region encompassing exons 5-10 failed to confirm the presence of the c.844 CϾT (R282X) mutation in exon 9 in proband I.1 (Family 1), suggesting that only one mutant allele was expressed in fibroblasts.
X
ABCA1 p.Arg282* 12576507:185:142
status: NEW211 ABCA1 cDNA region spanning from exon 5 to exon 10 was amplified by PCR and digested with Af l III to detect the c.844 CϾT mutation (R282X) in exon 9.
X
ABCA1 p.Arg282* 12576507:211:138
status: NEW274 One of the mutations found in proband I.1 (Family 1) is a nonsense mutation in exon 9 (R282X) that involves a CpG dinucleotide, a well-recognized hot spot for base substitution (39).
X
ABCA1 p.Arg282* 12576507:274:87
status: NEW0 Copyright (c) 2003 by Lipid Research, Inc. 254 Journal of Lipid Research Volume 44, 2003 This article is available online at http://www.jlr.org Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 5GC mutation in ABCA1 gene Serena Altilia,* Livia Pisciotta,ߤ Rita Garuti,* Patrizia Tarugi,* Alfredo Cantafora,&#a7; Laura Calabresi,** Jacopo Tagliabue,ߤߤ Sergio Maccari,&#a7;&#a7; Franco Bernini,*** Ilaria Zanotti,*** Carlo Vergani,ߤߤ Stefano Bertolini,ߤ and Sebastiano Calandra1,** Department of Biomedical Sciences,* University of Modena and Reggio Emilia; Department of Internal Medicine,ߤ University of Genoa; National Institute of Health,&#a7; Rome; Department of Pharmacological Sciences,** Center "E. Grossi Paoletti," University of Milan; Ospedale Maggiore-IRCCS,ߤߤ Milan; Sant`Anna Hospital,&#a7;&#a7; Castelnuovo Monti, Reggio Emilia; and Departments of Pharmacological*** and Biological Sciences and Applied Chemistries, University of Parma, Italy Abstract Two point mutations of ABCA1 gene were found in a patient with Tangier disease (TD): i) GC in intron 2 (IVS2 5GC) and ii) c.844 CT in exon 9 (R282X).
X
ABCA1 p.Arg282* 12576507:0:1186
status: NEW78 The R282X mutation and the cosegregating haplotype are indicated by red color (see sequence analysis in Fig. 3).
X
ABCA1 p.Arg282* 12576507:78:4
status: NEW164 The sequence of ABCA1 gene revealed that proband I.1 (Family 1) was a compound heterozygote for: i) a GC transversion at the 5th nucleotide of intron 2 (IVS2 5GC), and ii) a c.844 CT transition in exon 9, which converts the arginine codon at position 282 into a termination codon (R282X) (Fig. 3).
X
ABCA1 p.Arg282* 12576507:164:285
status: NEW167 The c.844 CT mutation (R282X) introduces a new AflIII restriction site.
X
ABCA1 p.Arg282* 12576507:167:24
status: NEW169 The proband`s brother was heterozygous for the nonsense mutation in exon 9 (R282X).
X
ABCA1 p.Arg282* 12576507:169:76
status: NEW173 Haplotype analysis The genotyping of five polymorphic markers close to or within the ABCA1 gene demonstrated: i) the IVS2 5GC mutation co-segregates with haplotype a; ii) the probands of Family 1 and Family 2 share this haplotype; iii) the nonsense mutation (R282X) cosegregates with haplotype b (Fig. 1).
X
ABCA1 p.Arg282* 12576507:173:261
status: NEW178 Skin fibroblasts from a control subject, proband I.1 of Family 1 (IVS2 5GC/ R282X), and another TD patient (homozygous for R587W) reported previously (13) were labeled with [3H]cholesterol and then incubated in the presence or in the absence of 22-hydroxycholesterol and 9-cis-retinoic acid (22ch/RA).
X
ABCA1 p.Arg282* 12576507:178:78
status: NEW184 Analysis of cDNA Unexpectedly, the sequence of the cDNA region encompassing exons 5-10 failed to confirm the presence of the c.844 CT (R282X) mutation in exon 9 in proband I.1 (Family 1), suggesting that only one mutant allele was expressed in fibroblasts.
X
ABCA1 p.Arg282* 12576507:184:136
status: NEW210 ABCA1 cDNA region spanning from exon 5 to exon 10 was amplified by PCR and digested with Af l III to detect the c.844 CT mutation (R282X) in exon 9.
X
ABCA1 p.Arg282* 12576507:210:132
status: NEW273 One of the mutations found in proband I.1 (Family 1) is a nonsense mutation in exon 9 (R282X) that involves a CpG dinucleotide, a well-recognized hot spot for base substitution (39).
X
ABCA1 p.Arg282* 12576507:273:87
status: NEW